The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Open accessAbstract
BACKGROUND: Approximately 50 to 60% of patients with essential thrombocythemia or primary myelofibrosis carry a mutation in the Janus kinase 2 gene (JAK2), and an additional 5 to 10% have activating mutations in the thrombopoietin receptor gene (MPL). So far, no specific molecular marker has been identified in the remaining 30 to 45% of patients. METHODS: We performed whole-exome sequencing to identify somatically acquired mutations in six patients who had primary myelofibrosis without mutations in JAK2 or MPL. Resequencing of CALR, encoding calreticulin, was then performed in cohorts of patients with myeloid neoplasms. RESULTS: Somatic insertions or deletions in exon 9 of CALR were detected in all patients who underwent whole-exome sequencing. Resequencing in 1107 samples from patients with myeloproliferative neoplasms showed that CALR mutations were absent in polycythemia vera. In essential thrombocythemia and primary myelofibrosis, CALR mutations and JAK2 and MPL mutations were mutually exclusive. Among patients with essential thrombocythemia or primary myelofibrosis with nonmutated JAK2 or MPL, CALR mutations were detected in 67% of those with essential thrombocythemia and 88% of those with primary myelofibrosis. A total of 36 types of insertions or deletions were identified that all cause a frameshift to the same alternative reading frame and generate a novel C-terminal peptide in the mutant calreticulin. Overexpression of the most frequent CALR deletion caused cytokine-independent growth in vitro owing to the activation of signal transducer and activator of transcription 5 (STAT5) by means of an unknown mechanism. Patients with mutated CALR had a lower risk of thrombosis and longer overall survival than patients with mutated JAK2. CONCLUSIONS: Most patients with essential thrombocythemia or primary myelofibrosis that was not associated with a JAK2 or MPL alteration carried a somatic mutation in CALR. The clinical course in these patients was more indolent than that in patients with the JAK2 V617F mutation. (Funded by the MPN Research Foundation and Associazione Italiana per la Ricerca sul Cancro.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Calreticulin gene (CALR) mutations frequently occur in Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), primary myelofibrosis (PMF), and polycythemia vera (PV) [188–190].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [189]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Self-citationMutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E. P., Ebert, B. L., Gozo, M. C., Cuker, A. C., Wernig, G., Moore, S. A., Galinsky, I. A., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,445
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
Scott, L. M., Tong, W., Levine, R. L., Scott, M., Beer, P., Stratton, M. R., Futreal, P., Erber, W., McMullin, M., Harrison, C. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065202 · Cited by 1,346
The Analysis of Failure Times in the Presence of Competing Risks
Prentice, R. L., Kalbfleisch, J. D., Peterson, A. V., Flournoy, N., Farewell, V. T., & Breslow, N. E. (1978) · Biometrics · doi:10.2307/2530374 · Cited by 1,266
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139
Passamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E. M., Caramella, M., Maffioli, M., et al. (2009) · Blood · doi:10.1182/blood-2009-09-245837 · Cited by 997
Self-citationMutations and prognosis in primary myelofibrosis
Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A. D., Pereira, A., Finke, C. M., Score, J., Gangat, N., Mannarelli, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.119 · Cited by 793
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
EASL Clinical Practice Guidelines: Vascular diseases of the liver
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.040 · Cited by 817
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Chen, X., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 797
Tefferi, A., Guglielmelli, P., Larson, D. R., Finke, C. M., Wassie, E. A., Pieri, L., Gangat, N., Fjerza, R., Belachew, A. A., Lasho, T. L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-579136 · Cited by 748
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
Vainchenker, W., & Královics, R. (2016) · Blood · doi:10.1182/blood-2016-10-695940 · Cited by 716
Barbui, T., Thiele, J., Gisslinger, H., Kvasnicka, H. M., Vannucchi, A. M., Guglielmelli, P., Orazi, A., & Tefferi, A. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0054-y · Cited by 644
Self-citationThe role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
Thomas, S. J., Snowden, J. A., Zeidler, M. P., & Danson, S. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.233 · Cited by 661
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Lundberg, P., Karow, A., Nienhold, R., Looser, R., Hao-Shen, H., Nissen, I., Girsberger, S., Lehmann, T., Passweg, J. R., Stern, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-537167 · Cited by 661
Rumi, E., Pietra, D., Ferretti, V. V., Klampfl, T., Harutyunyan, A. S., Feenstra, J. D. M., Them, N. C. C., Berg, T., Elena, C., Casetti, I. C., et al. (2013) · Blood · doi:10.1182/blood-2013-11-539098 · Cited by 602
Self-citationBarbui, T., Tefferi, A., Vannucchi, A. M., Passamonti, F., Silver, R. T., Hoffman, R., Verstovšek, S., Mesa, R. A., Kiladjian, J., Hehlmann, R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0077-1 · Cited by 592
Tefferi, A., Lasho, T. L., Finke, C. M., Knudson, R. A., Ketterling, R. P., Hanson, C., Maffioli, M., Caramazza, D., Passamonti, F., & Pardanani, A. D. (2014) · Leukemia · doi:10.1038/leu.2014.3 · Cited by 547
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
Pardanani, A. D., Harrison, C. N., Cortes, J. E., Cervantes, F., Mesa, R. A., Milligan, D. W., Masszi, T., Mishchenko, E., Jourdan, É., Vannucchi, A. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1590 · Cited by 497
Wolach, O., Sellar, R. S., Martinod, K., Cherpokova, D., McConkey, M., Chappell, R. J., Silver, A. J., Adams, D., Castellano, C. A., Schneider, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8292 · Cited by 481
The sequences of 150,119 genomes in the UK Biobank
Halldorsson, B. V., Eggertsson, H. P., Moore, K. H. S., Hauswedell, H., Eiriksson, O., Ulfarsson, M. O., Palsson, G., Hardarson, M. T., Oddsson, A., Jensson, B. O., et al. (2022) · Nature · doi:10.1038/s41586-022-04965-x · Cited by 448
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms
Arranz, L., Sánchez-Aguilera, A., Martín-Pérez, D., Isern, J., Langa, X., Tzankov, A., Lundberg, P., Muntión, S., Tzeng, Y.-S., Lai, D.-M., et al. (2014) · Nature · doi:10.1038/nature13383 · Cited by 444
for the COMFORT-I investigators, Verstovšek, S., Mesa, R. A., Gotlib, J. R., Gupta, V. K., DiPersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0417-z · Cited by 446
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts
Malcovati, L., Karimi, M., Papaemmanuil, E., Ambaglio, I., Jädersten, M., Jansson, M., Elena, C., Gallì, A., Walldin, G., Della Porta, M. G., et al. (2015) · Blood · doi:10.1182/blood-2015-03-633537 · Cited by 434
Self-citationRampal, R. K., Al‐Shahrour, F., Abdel-Wahab, O. I., Patel, J. P., Brunel, J.-P., Mermel, C. H., Bass, A. J., Pretz, J. L., Ahn, J., Hricik, T., et al. (2014) · Blood · doi:10.1182/blood-2014-02-554634 · Cited by 444
Rotunno, G., Mannarelli, C., Guglielmelli, P., Pacilli, A., Pancrazzi, A., Pieri, L., Fanelli, T., Bosi, A., & Vannucchi, A. M. (2013) · Blood · doi:10.1182/blood-2013-11-538983 · Cited by 415
Fucikova, J. P., Špíšek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Research · doi:10.1038/s41422-020-0383-9 · Cited by 422
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
Rumi, E., Pietra, D., Pascutto, C., Guglielmelli, P., Martínez‐Trillos, A., Casetti, I. C., Colomer, D., Pieri, L., Pratcorona, M., Rotunno, G., et al. (2014) · Blood · doi:10.1182/blood-2014-05-578435 · Cited by 397
Self-citationMesa, R. A., Kiladjian, J., Catalano, J. V., Devos, T., Egyed, M., Hellman, A., McLornan, D. P., Shimoda, K., Winton, E. F., Deng, W., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.4418 · Cited by 405
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.038 · Cited by 384
Tefferi, A., & Barbui, T. (2020) · American Journal of Hematology · doi:10.1002/ajh.26008 · Cited by 365
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
Chachoua, I., Pecquet, C., El-Khoury, M., Nivarthi, H., Albu, R.-I., Marty, C., Gryshkova, V., Defour, J., Vertenoeil, G., Ngo, A., et al. (2015) · Blood · doi:10.1182/blood-2015-11-681932 · Cited by 351
Self-citationUncovering novel mutational signatures by de novo extraction with SigProfilerExtractor
Islam, S. M. A., Díaz‐Gay, M., Wu, Y., Barnes, M. D., Vangara, R., Bergstrom, E. N., He, Y., Vella, M., Wang, J., Teague, J. W., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100179 · Cited by 364
Tefferi, A., & Pardanani, A. D. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.89 · Cited by 354
Verstovšek, S., Mesa, R. A., Gotlib, J. R., Levy, R. S., Gupta, V. K., DiPersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.115840 · Cited by 339
Somatic mutations and cell identity linked by Genotyping of Transcriptomes
Nam, A. S., Kim, K.-T., Chaligne, R., Izzo, F., Ang, C., Taylor, J., Myers, R. M., Abu-Zeinah, G., Brand, R., Omans, N. D., et al. (2019) · Nature · doi:10.1038/s41586-019-1367-0 · Cited by 333
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Yang, K., Halima, A., & Chan, T. A.-T. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 352
Current and future status of JAK inhibitors
McLornan, D. P., Pope, J. E., Gotlib, J. R., & Harrison, C. N. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00438-4 · Cited by 336
Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo
Woll, P. S., Kjällquist, U., Chowdhury, O., Doolittle, H., Wedge, D. C., Thongjuea, S., Erlandsson, R., Ngara, M., Anderson, K., Deng, Q., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.036 · Cited by 333
Self-citationKleppe, M., Kwak, M., Koppikar, P., Riester, M., Keller, M., Bastian, L., Hricik, T., Bhagwat, N., McKenney, A. S., Papalexi, E., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0736 · Cited by 325
Targeted deep sequencing in polycythemia vera and essential thrombocythemia
Tefferi, A., Lasho, T. L., Guglielmelli, P., Finke, C. M., Rotunno, G., Elala, Y. C., Pacilli, A., Hanson, C. A., Pancrazzi, A., Ketterling, R. P., et al. (2016) · Blood Advances · doi:10.1182/bloodadvances.2016000216 · Cited by 324
Guglielmelli, P., Lasho, T. L., Rotunno, G., Score, J., Mannarelli, C., Pancrazzi, A., Biamonte, F., Pardanani, A. D., Zoi, K., Reiter, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.76 · Cited by 311
Self-citationPietra, D., Rumi, E., Ferretti, V. V., Buduo, C. A. D., Milanesi, C., Cavalloni, C., Sant’Antonio, E., Abbonante, V., Moccia, F. D., Casetti, I. C., et al. (2015) · Leukemia · doi:10.1038/leu.2015.277 · Cited by 306
Self-citationGenomic and functional analysis of leukemic transformation of myeloproliferative neoplasms
Rampal, R., Ahn, J., Abdel-Wahab, O., Nahas, M., Wang, K., Lipson, D., Otto, G. A., Yelensky, R., Hricik, T., McKenney, A. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407792111 · Cited by 301
Araki, M., Yang, Y., Masubuchi, N., Hironaka, Y., Takei, H., Morishita, S., Mizukami, Y., Kan, S., Shirane, S., Edahiro, Y., et al. (2016) · Blood · doi:10.1182/blood-2015-09-671172 · Cited by 319
Malcovati, L., Stevenson, K. E., Papaemmanuil, E., Neuberg, D. S., Bejar, R. L., Boultwood, J., Bowen, D., Campbell, P. J., Ebert, B. L., Fenaux, P., et al. (2020) · Blood · doi:10.1182/blood.2020004850 · Cited by 304
Self-citationElf, S., Abdelfattah, N. S., Chen, E., Perales-Patón, J., Rosen, E. A., Ko, A., Peisker, F., Florescu, N., Giannini, S., Wolach, O., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1434 · Cited by 293
Feenstra, J. D. M., Nivarthi, H., Gisslinger, H., Leroy, E., Rumi, E., Chachoua, I., Bagienski, K., Kubešová, B., Pietra, D., Gisslinger, B., et al. (2015) · Blood · doi:10.1182/blood-2015-07-661835 · Cited by 292
Self-citationKröger, N. M., Deeg, H. J., Olavarría, E., Niederwieser, D. W., Bacigalupo, A. P., Barbui, T., Rambaldi, A., Mesa, R. A., Tefferi, A., Grießhammer, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.233 · Cited by 279
Kleppe, M., Koche, R., Zou, L., van Galen, P., Hill, C. E., Dong, L., De Groote, S., Papalexi, E., Hanasoge Somasundara, A. V., Cordner, K., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.009 · Cited by 279
Tefferi, A., Guglielmelli, P., Lasho, T. L., Rotunno, G., Finke, C. M., Mannarelli, C., Belachew, A. A., Pancrazzi, A., Wassie, E. A., Ketterling, R. P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.57 · Cited by 279
Marty, C., Pecquet, C., Nivarthi, H., El-Khoury, M., Chachoua, I., Tulliez, M., Villeval, J., Raslová, H., Královics, R., Constantinescu, S. N., et al. (2015) · Blood · doi:10.1182/blood-2015-11-679571 · Cited by 274
Self-citationSchneider, R. K., Mullally, A., Dugourd, A. J. F., Peisker, F., Hoogenboezem, R. M., van Strien, P. M. H., Bindels, E. M., Heckl, D., Büsche, G., Fleck, D., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.03.008 · Cited by 281
Hultcrantz, M., Björkholm, M., Dickman, P. W., Landgren, O., Derolf, Å. R., Kristinsson, S. Y., & Andersson, T. M. L. (2018) · Annals of Internal Medicine · doi:10.7326/m17-0028 · Cited by 268
Tefferi, A., & Barbui, T. (2015) · American Journal of Hematology · doi:10.1002/ajh.23895 · Cited by 268
Hinds, D. A., Barnholt, K. E., Mesa, R. A., Kiefer, A. K., Do, C. B., Eriksson, N., Mountain, J. L., Francke, U., Tung, J. Y., Nguyen, H. (., et al. (2016) · Blood · doi:10.1182/blood-2015-06-652941 · Cited by 267
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms
Rumi, E., & Cazzola, M. (2016) · Blood · doi:10.1182/blood-2016-10-695957 · Cited by 263
Self-citationDiagnosis and classification of hematologic malignancies on the basis of genetics
Taylor, J., Xiao, W., & Abdel-Wahab, O. I. (2017) · Blood · doi:10.1182/blood-2017-02-734541 · Cited by 260
Cerquozzi, S., & Tefferi, A. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.95 · Cited by 249
Tefferi, A., & Barbui, T. (2018) · American Journal of Hematology · doi:10.1002/ajh.25303 · Cited by 240
How common are myeloproliferative neoplasms? A systematic review and meta‐analysis
Titmarsh, G. J., Duncombe, A. S., McMullin, M. F., O’Rorke, M. A., Mesa, R. A., de Vocht, F., Horan, S., Fritschi, L., Clarke, M. J., & Anderson, L. A. (2014) · American Journal of Hematology · doi:10.1002/ajh.23690 · Cited by 235
Tefferi, A., & Barbui, T. (2016) · American Journal of Hematology · doi:10.1002/ajh.24607 · Cited by 233
Whole-genome sequencing of 490,640 UK Biobank participants
Manuscript Writing Group, Carss, K., Halldórsson, B. V., Hou, L., Liu, J. Z., Wheeler, E., Lo, Y., Kundu, K., Huang, Z., Lacey, B., et al. (2025) · Nature · doi:10.1038/s41586-025-09272-9 · Cited by 236
Reinisch, A., Thomas, D., Corces, M. R., Zhang, X., Gratzinger, D. A., Hong, W., Schallmoser, K., Strunk, D., & Majeti, R. (2016) · Nature Medicine · doi:10.1038/nm.4103 · Cited by 229
Bersanelli, M., Travaglino, E., Meggendorfer, M., Matteuzzi, T., Sala, C., Mosca, E., Chiereghin, C., Nanni, N. D., Gnocchi, M., Zampini, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01659 · Cited by 228
JAK-STAT signaling in cancer: From cytokines to non-coding genome
Pěnčík, J., Pham, H. T. T., Schmoellerl, J., Javaheri, T., Schlederer, M., Čulig, Z., Merkel, O., Moriggl, R., Grebien, F., & Kenner, L. (2016) · Cytokine · doi:10.1016/j.cyto.2016.06.017 · Cited by 221
Tefferi, A., Wassie, E. A., Guglielmelli, P., Gangat, N., Belachew, A. A., Lasho, T. L., Finke, C. M., Ketterling, R. P., Hanson, C. A., Pardanani, A. D., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23743 · Cited by 216
Tefferi, A., Thiele, J., Vannucchi, A. M., & Barbui, T. (2014) · Leukemia · doi:10.1038/leu.2014.35 · Cited by 216
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
Elli, E. M., Baratè, C., Mendicino, F., Palandri, F., & Palumbo, G. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01186 · Cited by 212
Wang, S. A., Hasserjian, R. P., Fox, P. S., Rogers, H. J., Geyer, J. T., Chabot‐Richards, D., Weinzierl, E. P., Hatem, J., Jaso, J. M., Kanagal‐Shamanna, R., et al. (2014) · Blood · doi:10.1182/blood-2014-02-553800 · Cited by 205
The intrinsic and extrinsic effects of N-linked glycans on glycoproteostasis
Hebert, D. N., Lamriben, L., Powers, E. T., & Kelly, J. W. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1651 · Cited by 206
Cazzola, M., & Královics, R. (2014) · Blood · doi:10.1182/blood-2014-03-530865 · Cited by 202
Self-citationTelomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia
Baerlocher, G. M., Leibundgut, E. O., Ottmann, O. G., Spitzer, G., Odenike, O. M., McDevitt, M. A., Röth, A., Daskalakis, M., Burington, B. E., Stuart, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503479 · Cited by 199
Cabagnols, X., Favale, F., Pasquier, F., Messaoudi, K., Defour, J., Ianotto, J., Marzac, C., Couedic, J. P. L., Droin, N. M., Chachoua, I., et al. (2015) · Blood · doi:10.1182/blood-2015-07-661983 · Cited by 206
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
Zahr, A. A., Salama, M. E., Carreau, N. A., Tremblay, D. A., Verstovšek, S., Mesa, R. A., Hoffman, R., & Mascarenhas, J. O. (2016) · Haematologica · doi:10.3324/haematol.2015.141283 · Cited by 205
Gagelmann, N., Ditschkowski, M., Bogdanov, R., Bredin, S., Robin, M., Cassinat, B., Shahswar, R., Thol, F. R., Heuser, M., Socié, G., et al. (2019) · Blood · doi:10.1182/blood-2018-12-890889 · Cited by 189
for the Study Alliance Leukemia (SAL), Kaifie, A., Kirschner, M., Wolf, D. G. F., Maintz, C., Hänel, M., Gattermann, N., Goekkurt, E., Platzbecker, U., Hollburg, W., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0242-9 · Cited by 185
Psaila, B., Wang, G., Rodriguez-Meira, A., Li, R., Heuston, E. F., Murphy, L., Yee, D., Hitchcock, I. S., Sousos, N., O’Sullivan, J., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.008 · Cited by 185
Kluk, M., Lindsley, R. C., Aster, J. C., Lindeman, N. I., Szeto, D. P., Hall, D., & Kuo, F. C. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.02.003 · Cited by 180
Myeloproliferative neoplasm stem cells
Mead, A. J., & Mullally, A. (2017) · Blood · doi:10.1182/blood-2016-10-696005 · Cited by 187
Myeloproliferative neoplasms: A decade of discoveries and treatment advances
Tefferi, A. (2015) · American Journal of Hematology · doi:10.1002/ajh.24221 · Cited by 186
N‐Glycan‐based ER Molecular Chaperone and Protein Quality Control System: The Calnexin Binding Cycle
Lamriben, L., Graham, J. B., Adams, B. M., & Hebert, D. N. (2015) · Traffic · doi:10.1111/tra.12358 · Cited by 184
Genetic basis and molecular profiling in myeloproliferative neoplasms
Paz, D. L., Královics, R., & Skoda, R. C. (2022) · Blood · doi:10.1182/blood.2022017578 · Cited by 189
Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation
Gu, Z., Liu, Y., Cai, F., Patrick, M., Zmajkovic, J., Cao, H., Zhang, Y., Tasdogan, A., Chen, M., Qi, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0152 · Cited by 173
Deininger, M., Radich, J., Burn, T. C., Huber, R., Paranagama, D., & Verstovsek, S. (2015) · Blood · doi:10.1182/blood-2015-03-635235 · Cited by 173
Koschmieder, S., Mughal, T. I., Hasselbalch, H. C., Barosi, G., Valent, P., Kiladjian, J., Jeryczynski, G., Gisslinger, H., Jutzi, J. S., Pahl, H. L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.12 · Cited by 179
Self-citationShiozawa, Y., Malcovati, L., Gallì, A., Sato‐Otsubo, A., Kataoka, K., Sato, Y., Watatani, Y., Suzuki, H., Yoshizato, T., Yoshida, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06063-x · Cited by 179
Self-citationSzuber, N., Mudireddy, M., Nicolosi, M., Penna, D., Vallapureddy, R. R., Lasho, T. L., Finke, C. M., Begna, K. H., Elliott, M. A., Hook, C. C., et al. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.022 · Cited by 172
Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis
Decker, M., Martínez-Morentin, L., Wang, G., Lee, Y., Liu, Q., Leslie, J. S., & Ding, L. (2017) · Nature Cell Biology · doi:10.1038/ncb3530 · Cited by 175
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms
Tapper, W., Jones, A. V., Královics, R., Harutyunyan, A. S., Zoi, K., Leung, W. C. Y., Godfrey, A. L., Guglielmelli, P., Callaway, A., Ward, D., et al. (2015) · Nature Communications · doi:10.1038/ncomms7691 · Cited by 175
Self-citationJAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
Vainchenker, W., Leroy, E., Gilles, L., Marty, C., Plo, I., & Constantinescu, S. N. (2018) · F1000Research · doi:10.12688/f1000research.13167.1 · Cited by 167
Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors
Meyer, S. C., & Levine, R. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0279 · Cited by 168
Verger, E., Cassinat, B., Chauveau, A., Dosquet, C., Giraudier, S., Schlageter, M., Ianotto, J., Yassin, M. A., Al-Dewik, N. I. E., Carillo, S., et al. (2015) · Blood · doi:10.1182/blood-2015-07-659060 · Cited by 176
Thrombophilia testing: A British Society for Haematology guideline
Arachchillage, D. J., Mackillop, L. H., Chandratheva, A., Motawani, J., MacCallum, P., & Laffan, M. (2022) · British Journal of Haematology · doi:10.1111/bjh.18239 · Cited by 164
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management
Tefferi, A., Vannucchi, A. M., & Barbui, T. (2024) · American Journal of Hematology · doi:10.1002/ajh.27216 · Cited by 172
Current practices and guidelines for clinical next-generation sequencing oncology testing
Strom, S. P., & Strom, S. P. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0004 · Cited by 163
Cervantes, F. (2014) · Blood · doi:10.1182/blood-2014-07-575373 · Cited by 164
Meyer, S. C., Keller, M. D., Chiu, S., Koppikar, P., Guryanova, O. A., Rapaport, F., Xu, K., Manova, K., Pankov, D., O’Reilly, R. J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.06.006 · Cited by 166
Myeloproliferative neoplasms: from origins to outcomes
Nangalia, J., & Green, A. R. (2017) · Blood · doi:10.1182/blood-2017-06-782037 · Cited by 167
Tefferi, A., Lasho, T. L., Tischer, A., Wassie, E. A., Finke, C. M., Belachew, A. A., Ketterling, R. P., Hanson, C. A., & Pardanani, A. D. (2014) · Blood · doi:10.1182/blood-2014-07-588426 · Cited by 159
Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis
Verstovšek, S., Manshouri, T., Pilling, D., Bueso-Ramos, C., Newberry, K. J., Prijić, S., Knez, L., Božinović, K., Harris, D., Spaeth, E. L., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20160283 · Cited by 164
Tefferi, A., Lasho, T. L., Finke, C. M., Belachew, A. A., Wassie, E. A., Ketterling, R. P., Hanson, C. A., & Pardanani, A. D. (2014) · Leukemia · doi:10.1038/leu.2014.83 · Cited by 158
Cazzola, M. (2016) · Blood · doi:10.1182/blood-2016-03-657379 · Cited by 158
Self-citationAntiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
Álvarez‐Larrán, A., Pereira, A., Guglielmelli, P., Hernández‐Boluda, J. C., Arellano‐Rodrigo, E., Ferrer‐Marín, F., Alimam, S., Grießhammer, M., Kerguelen, A., Andréasson, B., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.146654 · Cited by 155
Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
Porpaczy, E., Tripolt, S., Hoelbl-Kovacic, A., Gisslinger, B., Bago-Horvath, Z., Casanova-Hevia, E., Clappier, E., Decker, T., Fajmann, S., Fux, D. A., et al. (2018) · Blood · doi:10.1182/blood-2017-10-810739 · Cited by 151
Self-citationTargeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
Wen, Q. J., Yang, Q., Goldenson, B., Malinge, S., Lasho, T. L., Schneider, R. K., Breyfogle, L. J., Schultz, R. F., Gilles, L., Koppikar, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3995 · Cited by 157
Harrison, C. N., Koschmieder, S., Foltz, L. M., Guglielmelli, P., Flindt, T., Koehler, M., Mathias, J., Komatsu, N., Boothroyd, R. N., Spierer, A., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3082-y · Cited by 149
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Gerds, A. T., Gotlib, J. R., Ali, H., Bose, P., Dunbar, A. J., Elshoury, A., George, T. I., Gundabolu, K., Hexner, E. O., Hobbs, G. S., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0046 · Cited by 139
Metadata
- Authors
- Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., Chen, D., Vladimer, G. I., Bagienski, K., Milanesi, C., Casetti, I. C., Sant'Antonio, E., Ferretti, V., Elena, C., Schischlik, F., Cleary, C., Six, M., Schalling, M., Schönegger, A., Bock, C., Malcovati, L., Pascutto, C., Superti-Furga, G., Cazzola, M., & Kralovics, R.
- Affiliations
- Austrian Academy of Sciences (AT)
- Medical University of Vienna (AT)
- Policlinico San Matteo Fondazione (IT)
- University of Pavia (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-12-19
- Volume
- 369
- Issue
- 25
- Pages
- 2379-2390
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2157694607
- Cited by
- 2,003
- References
- 32
- Citations by year
- 2026: 80 · 2025: 63 · 2024: 81 · 2023: 117 · 2022: 122 · 2021: 173 · 2020: 144 · 2019: 146 · 2018: 153 · 2017: 200 · 2016: 247 · 2015: 243 · 2014: 222 · 2013: 7
- FWCI
- 118.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- calreticulin, CALR mutation, myeloproliferative neoplasms, essential thrombocythemia, primary myelofibrosis, JAK2 V617F mutation, MPL mutation, somatic mutations, exon 9 deletion, frameshift mutation, STAT5 activation, thrombosis risk, overall survival
- MeSH terms
- Bone Marrow Diseases, Exons, Humans, Leukemia, Myeloid, Mutation, Thrombocythemia, Essential, Thrombosis, Proportional Hazards Models, Polymerase Chain Reaction, Sequence Analysis, DNA, Calreticulin, Janus Kinase 2, Receptors, Thrombopoietin, Primary Myelofibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
